JP2022526495A - 胃腸疾患および障害を治療するための組成物およびその方法 - Google Patents

胃腸疾患および障害を治療するための組成物およびその方法 Download PDF

Info

Publication number
JP2022526495A
JP2022526495A JP2021556420A JP2021556420A JP2022526495A JP 2022526495 A JP2022526495 A JP 2022526495A JP 2021556420 A JP2021556420 A JP 2021556420A JP 2021556420 A JP2021556420 A JP 2021556420A JP 2022526495 A JP2022526495 A JP 2022526495A
Authority
JP
Japan
Prior art keywords
rifaximin
antibiotics
mucolytic agent
nac
ibs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526495A5 (https=
Inventor
ピメンタル，マーク
ギマラエス ソウサ レイテ，ガブリエラ
メイサー，ルチ
レザイエ，アリ
モラレス，ウォルター
ワイツマン，ステイシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of JP2022526495A publication Critical patent/JP2022526495A/ja
Publication of JP2022526495A5 publication Critical patent/JP2022526495A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021556420A 2019-03-18 2020-03-18 胃腸疾患および障害を治療するための組成物およびその方法 Pending JP2022526495A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819986P 2019-03-18 2019-03-18
US62/819,986 2019-03-18
PCT/US2020/023396 WO2020191076A1 (en) 2019-03-18 2020-03-18 Compositions and methods to treat gastrointestinal diseases and disorders

Publications (2)

Publication Number Publication Date
JP2022526495A true JP2022526495A (ja) 2022-05-25
JP2022526495A5 JP2022526495A5 (https=) 2023-03-14

Family

ID=72520533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556420A Pending JP2022526495A (ja) 2019-03-18 2020-03-18 胃腸疾患および障害を治療するための組成物およびその方法

Country Status (7)

Country Link
US (1) US20230038019A1 (https=)
EP (1) EP3941461A4 (https=)
JP (1) JP2022526495A (https=)
CN (1) CN113645968A (https=)
AU (2) AU2020240069B2 (https=)
CA (2) CA3132400A1 (https=)
WO (1) WO2020191076A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205650A1 (en) * 2022-04-20 2023-10-26 Cedars-Sinai Medical Center Methods of diagnosing ibs-d and selection of ibs-d treatment
US20250275950A1 (en) * 2022-05-19 2025-09-04 Cedars-Sinai Medical Center Rifaximin and n-acetyl cysteine formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264409A1 (en) * 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
JP2016520108A (ja) * 2013-05-29 2016-07-11 ザンボン ソシエタ ペル アチオニ 嚥下可能なｎ−アセチルシステイン錠剤
JP2017520624A (ja) * 2014-06-30 2017-07-27 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1235529A (en) * 1968-12-02 1971-06-16 Calbiochem Composition for mucolysis
TWI236905B (en) * 1997-10-28 2005-08-01 Jens Ponikau Pharmaceutical composition for treating and preventing inflammation of mucosal tissue
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005118860A2 (en) * 2004-04-09 2005-12-15 General Hospital Corporation Compositions and methods related to an intestinal inflammation and uses therefor
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
US20120283411A9 (en) * 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0823472D0 (en) * 2008-12-23 2009-01-28 Photocure Asa Product
JP2013518895A (ja) * 2010-02-03 2013-05-23 マイクロビオン コーポレーション 細菌バイオフィルムの処置および他の使用をはじめとする、生体医学的使用のための消毒薬としてのビスマス−チオール
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
WO2014070769A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
US20160158262A1 (en) * 2013-07-26 2016-06-09 Cedars-Sinai Medical Center Methods of treating irritable bowel syndrome
SG11201700621XA (en) * 2014-07-25 2017-02-27 Agency Science Tech & Res Antibiotic compositions for treating bacterial infections
DK3288554T3 (da) * 2015-04-30 2022-11-14 Probiotical Spa Anvendelse af antibiotika med specifikke terapeutiske aktiviteter kombineret med samtidig anvendelse af lactobacilli og/eller bifidobakterier med en ikke-overførbar antibiotisk resistens med den samme terapeutiske indikation
KR20190116320A (ko) * 2017-02-07 2019-10-14 에스티씨. 유엔엠 오래 지속되는 자가 포식 유도를 위한 동위 원소 강화 암브록솔

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264409A1 (en) * 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
JP2016520108A (ja) * 2013-05-29 2016-07-11 ザンボン ソシエタ ペル アチオニ 嚥下可能なｎ−アセチルシステイン錠剤
JP2017520624A (ja) * 2014-06-30 2017-07-27 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOMED. PAPERS, vol. 148, no. 2, JPN6024007359, 2004, pages 131 - 133, ISSN: 0005412307 *
中南薬学, vol. 5, no. 4, JPN6024007358, 2007, pages 296 - 299, ISSN: 0005412306 *

Also Published As

Publication number Publication date
EP3941461A4 (en) 2022-12-14
AU2020240069A1 (en) 2021-10-28
CA3293273A1 (en) 2026-03-02
AU2025271108A1 (en) 2025-12-18
EP3941461A1 (en) 2022-01-26
US20230038019A1 (en) 2023-02-09
CA3132400A1 (en) 2020-09-24
WO2020191076A1 (en) 2020-09-24
CN113645968A (zh) 2021-11-12
AU2020240069B2 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
TW202128183A (zh) 用於治療多種病症之方法及組成物
TW201521718A (zh) 低頻率格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之治療
RU2540513C2 (ru) Способы лечения печеночной энцефалопатии
AU2025271108A1 (en) Compositions and methods to treat gastrointestinal diseases and disorders
JPH06501937A (ja) 非炎症性及び非感染性腸障害の処置
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
RU2672871C2 (ru) Применение левоцетиризина и монтелукаста при лечении травматических повреждений
WO2006029036A2 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
RU2705097C2 (ru) Применение левоцетиризина и монтелукаста при лечении анафилаксии
WO2016120787A1 (en) Oral n-acetylcysteine in the treatment of upper respiratory tract infections and symptoms
Sykes Antimicrobial drug use in dogs and cats
JP2016525138A (ja) 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
Birkinshaw et al. Necrotising fasciitis as a complication of steroid injection.
RU2571268C2 (ru) Модуляция системного воздействия рифаксимина
JP2021535106A (ja) 消化管障害および喘息の処置におけるガボキサドールの使用
Cecil et al. Sulfadiazine in the Treatment of the Common Cold
JP2024541570A (ja) 内臓痛の処置のための医薬組成物
HK40064209A (en) Compositions and methods to treat gastrointestinal diseases and disorders
US20080159987A1 (en) Use of Rifaximin for the Treatment of Restless Legs Syndrome
Sykes et al. Antimicrobial Therapy in Dogs and Cats
US12337025B2 (en) Mutated e. coli enterotoxins as anti-inflammatory agents
Mero et al. Short-term tolerability of morniflumate in patients with cutaneous hypersensitivity reactions to non-steroidal anti-inflammatory drugs
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療
WO2006098607A1 (en) Histamine-containing composition for the treatment of allergic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408